Acticor Biotech SAS
Acticor Biotech SAS (ALACT.PA) Company Profile & Overview
Explore Acticor Biotech SAS’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.
Acticor Biotech SAS (ALACT.PA) Company Profile & Overview
Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome. The company was incorporated in 2013 and is headquartered in Paris, France.